Baxter International Inc. (NYSE: BAX) — This global medical products and services company is a leader in critical therapies for life-threatening conditions. The company’s profit margins are expected to improve from 2010′s 51.4%, and revenues are expected to rise by about 5%, according to S&P. But recent challenges to the health-care reform act, if successful, could have a strong positive impact on Baxter’s earnings, which are currently estimated to be $4.30 in 2011, up from $3.98 in 2010.
S&P maintains a “four-star buy” on the stock with a 12-month target of $58. But that target could be achieved much sooner if the recent triple-top is penetrated and the stock moves into the open gap at $52 to $58.Buy this high-quality health-care equipment maker on either a break from the top at $52 or a pullback to the 50-day moving average at $50.
No comments:
Post a Comment